Last update May 13, 2019
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Phenazopyridine Hydrochloride is also known as
Phenazopyridine Hydrochloride in other languages or writings:
Phenazopyridine Hydrochloride belongs to this group or family:
Main tradenames from several countries containing Phenazopyridine Hydrochloride in its composition:
|Tmax||2.48 ± 0.50||hours|
|T½||9.41 ± 2.04||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
An azo dye with analgesic effects on the urinary tract mucosa.
One of its metabolites is paracetamol.
It may discolour body fluids orange.
Oral administration 3 times a day.
Since the last update we have not found any published data on its excretion in breast milk.
It may cause kidney damage (Singh 2014) and methemoglobinemia (Banimahd 2016, Gold 2003).
There are few studies on its pharmacokinetics and it has limited efficacy.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity or glucose-6PD deficiency.